NCT00125502View on ClinicalTrials.gov

Recombinant CMV gB Vaccine in Postpartum Women

PHASE2CompletedINTERVENTIONAL
Enrollment

464

Participants

Timeline

Start Date

August 31, 1999

Primary Completion Date

June 30, 2007

Study Completion Date

January 31, 2010

Conditions
Cytomegalovirus Infections
Interventions
BIOLOGICAL

CMV gB vaccine

CMV gB is combined with a novel adjuvant, MF59, a proprietary oil-in-water emulsion, administered at 0, 1, and 6 months.

DRUG

MF59 adjuvant

Oil-in-water emulsion

DRUG

Placebo

Normal saline solution

Trial Locations (2)

35487

University of Alabama at Tuscaloosa, Tuscaloosa

35294-3293

University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (1)

MCM Vaccines B.V.
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

MCM Vaccines B.V.

INDUSTRY

lead

Robert Pass, MD

OTHER

NCT00125502 - Recombinant CMV gB Vaccine in Postpartum Women | Biotech Hunter | Biotech Hunter